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Abstract 
Background: The use of warfarin in patients with non‑valvular atrial fibrillation (NVAF) can be challenging. In this 
study, we evaluate the time in therapeutic range (TTR), health‑related quality of life (HRQoL) and treatment satisfac‑
tion of patients on long‑term warfarin for NVAF. The HRQoL and treatment satisfaction were compared based on the 
TTR.
Methods: A cross‑sectional study was conducted among patients on warfarin for NVAF who attended the antico‑
agulant clinic of a tertiary cardiology referral center in Sarawak from 1st June 2018 to 31st May 2019. Patients’ TTR was 
calculated by using Rosendaal technique, while their HRQoL and treatment satisfaction were assessed by using Short 
Form 12 Health Survey version 2 (SF12v2) and Duke Anticoagulant Satisfaction Scale (DASS), respectively.
Results: A total of 300 patients were included, with mean TTR score of 47.0 ± 17.3%. The physical component sum‑
mary (PCS) and mental component summary (MCS) score of SF‑12v2 were 47.0 ± 9.0 and 53.5 ± 9.6, respectively. The 
total score for DASS was 55.2 ± 21.3, while the score for limitations (L), hassles and burdens (H&B) and positive psycho‑
logical impacts (PPI) were 18.0 ± 10.0, 15.6 ± 9.1 and 21.6 ± 5.9, respectively. Seventy‑three (24.3%) patients had good 
TTR (≥ 60%), with mean of 70.2 ± 8.7%; while 227 (75.5%) patients with poor TTR had significantly lower mean of 
39.5 ± 11.9% (p = 0.006). There was no significant difference in the score of PCS (p = 0.150), MCS (p = 0.919) and each 
domain of SF‑12v2 (p = 0.184–0.684) between good and poor TTR, except for social functioning (p = 0.019). The total 
DASS score was also not significantly different between group (p = 0.779). Similar non‑significant difference was also 
reported in all the DASS sub dimensions (p = 0.502–0.699).
Conclusions: Majority of the patients on long‑term warfarin for NVAF in the current study have poor TTR. Their 
HRQoL and treatment satisfaction are independent of their TTR. Achieving a good TTR do not compromise the HRQoL 
and treatment satisfaction. Therefore, appropriate measures should be taken to optimise INR control, failing which 
direct oral anticoagulant therapy should be considered.
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Background
Atrial fibrillation (AF) is the commonest arrhythmia and 
represents substantial health care burden globally [1]. In 
2010, the estimated prevalence of AF was 592 per 100,000 
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